\u03b2-1,3/1,6-d-glucan Of Indonesian Ganoderma Lucidum Mycelium Extract Reduces Systolic Blood Pressure & Inflammation In Hypertensive Patients

Authors: Peter Sugita, MR Fadlan, Djanggan Sargowo, and A Rizal

Journal: Hypertension

Study Design:

• Intervention: Ganoderma Lucidum Mycelium Extract (GLME) 540mg/day + CCB/ACEI/ARB or placebo + CCB/ACEI
• Participants: 50 hypertensive adults (age 50-70 years)
• Duration: 90 days
• Outcome Measures:
  • Systolic blood pressure (SBP)
  • Diastolic blood pressure (DBP)
  • Mean arterial pressure (MAP)
  • Heart rate (HR), LVEF, LVMI
  • Inflammatory markers (hsCRP, MDA, TNF-\u03b1, IL-1, & IL-6)

Summary: This study investigated the effects of GLME, a compound derived from Ganoderma lucidum mushrooms, on blood pressure and inflammation in adults with hypertension. The study found that GLME significantly reduced systolic blood pressure compared to the placebo group. While it also lowered diastolic blood pressure, this change was not statistically significant compared to the placebo. The most significant reduction in systolic blood pressure was observed in the group receiving GLME alongside ACE inhibitors (ACEI) or angiotensin II receptor blockers (ARB). Additionally, GLME showed anti-inflammatory effects, particularly in the group receiving it with ACEI/ARB, as evidenced by a significant decrease in hsCRP, LVMI, TNF-\u03b1, IL-6, and IL-1\u03b2 levels. These findings suggest that GLME may be a beneficial supplement for managing hypertension and reducing inflammation.